Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT
Authors' conclusion
In people with overweight or obesity and established atherosclerotic cardiovascular disease but not diabetes, semaglutide reduced cardiovascular events irrespective of baseline HbA1c or change in HbA1c. Thus, semaglutide is expected to confer cardiovascular benefits in people with established atherosclerotic cardiovascular disease who are normoglycemic at baseline and/or in those without HbA1c improvements.
Study context
- Population
- People with overweight or obesity and atherosclerotic CVD without diabetes; mean age 61.6 years, 72.3% male; baseline HbA1c <5.7% for 33.5%, 5.7% to <6.0% for 34.6%, 6.0% to <6.5% for 31.9%
- Participants
- 17,604 people
- Comparison
- Weekly semaglutide 2.4 mg vs placebo, by baseline HbA1c and HbA1c change
- Primary endpoint
- First MACE:
- Cardiovascular mortality
- Nonfatal MI
- Stroke
Methodological detailsplacebo-controlled, intention-to-treat, Cox proportional hazards
- Placebo-controlled
- Intention-to-treat
- Cox proportional hazards
Primary result
As reported in the abstract
CV risk reduction with semaglutide vs placebo by baseline HbA1c and HbA1c change
- CV risk reduction not shown to be different across baseline HbA1c groups; consistent with overall study for all end points, except all-cause mortality
- CV outcomes consistent across subgroups of HbA1c change
- Intention-to-treat
Further findings
Primary end point of SELECT overall (first major adverse cardiovascular event (MACE))
- Reduced by 20% with semaglutide vs placebo
Original publication
Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT. Diabetes Care. Published 22 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →